Abraham Ludomirski is Director at Recro Pharma, Inc. (REPH). They have made 7 open-market trades across 3 companies since 2015, most recently 2026-01-02.
CIK 0001235402
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VSH | SELL | 2023-12-18 | 2023-12-19 | $23.84 | $3.6M | -2.1% | -7.5% | -10.8% |
| VSH | SELL | 2017-10-30 | 2017-10-30 | $21.79 | $436K | -1.4% | +1.6% | +3.2% |
| RWLK | SELL | 2016-06-02 | 2016-06-06 | $7.89 | $194K | -15.1% | -16.1% | -22.2% |
| REPH | SELL | 2016-05-20 | 2016-05-23 | $6.45 | $97K | +33.3% | +24.5% | +35.2% |
| REPH | SELL | 2015-11-27 | 2016-05-23 | $9.00 | $61K | +33.3% | +24.5% | +35.2% |
| REPH | SELL | 2015-11-23 | 2016-05-23 | $7.62 | $701K | +33.3% | +24.5% | +35.2% |
| REPH | SELL | 2015-11-23 | 2016-05-23 | $9.00 | $100K | +33.3% | +24.5% | +35.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.